{"title":"评论“是时候与路易体分享老年痴呆症的生物标志物结果了”。","authors":"John T O'Brien","doi":"10.1002/dad2.70145","DOIUrl":null,"url":null,"abstract":"<p><p>Many people with dementia with Lewy bodies (DLB) have evidence of Alzheimer's disease (AD) co-pathology, which can be assessed in vivo using biomarkers. In this issue, Armstrong and colleagues argue that it is now timely to disclose such AD biomarker results to people with DLB. They provide logical and powerful arguments, including the right for people to know and the value of this information in informing outcome and management. However, there are also important caveats to consider and a careful balance needs to be maintained between, on the one hand, the right to know and convey clinically useful information and, on the other, acknowledging the real uncertainty that exists regarding the true diagnostic and management implications of AD biomarkers in an individual with a DLB rather than an AD clinico-pathological syndrome.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70145"},"PeriodicalIF":4.4000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12238828/pdf/","citationCount":"0","resultStr":"{\"title\":\"Commentary on \\\"It is time to share Alzheimer biomarker results in dementia with Lewy bodies\\\".\",\"authors\":\"John T O'Brien\",\"doi\":\"10.1002/dad2.70145\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Many people with dementia with Lewy bodies (DLB) have evidence of Alzheimer's disease (AD) co-pathology, which can be assessed in vivo using biomarkers. In this issue, Armstrong and colleagues argue that it is now timely to disclose such AD biomarker results to people with DLB. They provide logical and powerful arguments, including the right for people to know and the value of this information in informing outcome and management. However, there are also important caveats to consider and a careful balance needs to be maintained between, on the one hand, the right to know and convey clinically useful information and, on the other, acknowledging the real uncertainty that exists regarding the true diagnostic and management implications of AD biomarkers in an individual with a DLB rather than an AD clinico-pathological syndrome.</p>\",\"PeriodicalId\":53226,\"journal\":{\"name\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"volume\":\"17 3\",\"pages\":\"e70145\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12238828/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/dad2.70145\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70145","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Commentary on "It is time to share Alzheimer biomarker results in dementia with Lewy bodies".
Many people with dementia with Lewy bodies (DLB) have evidence of Alzheimer's disease (AD) co-pathology, which can be assessed in vivo using biomarkers. In this issue, Armstrong and colleagues argue that it is now timely to disclose such AD biomarker results to people with DLB. They provide logical and powerful arguments, including the right for people to know and the value of this information in informing outcome and management. However, there are also important caveats to consider and a careful balance needs to be maintained between, on the one hand, the right to know and convey clinically useful information and, on the other, acknowledging the real uncertainty that exists regarding the true diagnostic and management implications of AD biomarkers in an individual with a DLB rather than an AD clinico-pathological syndrome.
期刊介绍：
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
